Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT

Bone Marrow Transplantation volume 57, pages 499–501 (2022)Cite this article

Subjects

Key points

  • Dara post-alloHCT does not appear to increase the incidence of GVHD

  • Superior PFS was seen in those with prior cGvHD

  • Infections are common

  • Extra-medullary disease progression is common

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Survival.

References

  1. Nikolaenko L, Chhabra S, Biran N, Chowdhury A, Hari P, Krishnan A, et al. Richter graft-versus-host disease in multiple myeloma patients treated with daratumumab after allogeneic transplantation. J Clin Lymphoma Myeloma Leuk. 2020;20:407–14.

    Article  Google Scholar 

  2. Gonzalez-Rodriguez AP, Lopez-Corral L, Moreno Fajardo DF, Gonzalez-Huerta AJ, Palomo P, Bermudez A, et al. Daratumumab is a safe and effective rescue therapy for multiple myeloma patients who relapse after allo-HSCT. Bone Marrow Transpl. 2020;55(Feb):461–3.

    Article  Google Scholar 

  3. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46.

    Article  Google Scholar 

  4. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825-8.

    CAS  Google Scholar 

  5. Shulman HM, Kleiner D, Lee SJ, MortonT, Pavletic SZ, Farmer E, et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transpl. 2006;12:31–47.

    Article  Google Scholar 

  6. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016;387(Apr):1551–60.

    Article  CAS  Google Scholar 

  7. Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, et al. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020;7:e447–55.

    Article  Google Scholar 

  8. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl J Med. 2016;375:1319–31.

    Article  CAS  Google Scholar 

  9. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksak M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl J Med. 2016;375(Aug):754–66.

    Article  CAS  Google Scholar 

  10. Vincent L, Ceballos P, Fegueux N, Plassot C, Méniane JC, Quittet P, et al. An analysis of relapse after allogeneic transplantation for Multiple Myeloma and results of salvage therapies. Blood Cancer J. 2015;5(Aug):e341.

    Article  CAS  Google Scholar 

  11. Rasche L, Röllig C, Stuhler G, Danhof S, Mielke S, Grigoleit GU, et al. Allogeneic hematopoietic cell transplantation in multiple myeloma: focus on longitudinal assessment of donor chimerism, extramedullary disease, and high-risk cytogenetic features. Biol Blood Marrow Transpl. 2016;22(Nov):1988–96.

    Article  Google Scholar 

Download references

Acknowledgements

We are grateful for all participating centers: Xavier Poiré, Cliniques Universitaires St. Luc, Brussels, Belgium; Nicolaas Schaap, Nijmegen Medical Center, Nijmegen, Netherlands; Jenny Byrne, Nottingham University, Nottingham, UK; Gandhi Damaj, CHU CAEN, Caen, France; Dries Deeren, AZ Delta, Roeselare, Belgium; Manos Nikolousis, Birmingham Heartlands Hospital, Birmingham, UK; Domenico Russo, USD Trapianti di Midollo, Adulti, Brescia, Italy; Joan Hendrik Veelken, Leiden University Hospital, Leiden, Netherlands; Claude Eric Bulabois, CHU Grenoble Alpes - Université Grenoble Alpes, Grenoble, France; Yves Chalandon, Département d’Oncologie, Service d’Hématologie, Geneva, Switzerland; Manuel Jurado Chacón, Hospital Univ. Virgen de las Nieves, Granada, Spain; Sonja Martin, Robert Bosch Krankenhaus, Stuttgart, Germany; Josep Maria Ribera Santasusana, ICO-Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Simona Sica, Universita Cattolica S. Cuore, Rome, Italy.

Author information

Authors and Affiliations

  1. CHU de Montpellier, Hôpital St Eloi, Montpellier, France

    Laure Vincent & Patrice Ceballos

  2. EBMT Statistical Unit, Leiden, The Netherlands

    Luuk Gras

  3. University of Freiburg, Freiburg, Germany

    Jürgen Finke

  4. University Hospital of Basel, Basel, Switzerland

    Jakob Passweg

  5. Hôpital St Louis, Paris, France

    Stéphanie Harel

  6. Barcelona Hospital Clinic, Barcelona, Spain

    Laura Rosinol

  7. University Medical Center Utrecht, Utrecht, Netherlands

    Monique Minnema

  8. University Hospital Carl Gustav Carus, Dresden, Germany

    Raphael Teipel

  9. University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

    Jaap van Doesum

  10. Klinikum Chemnitz, Chemnitz, Germany

    Mathias Hänel

  11. Centre Henri Becquerel, Rouen, France

    Pascal Lenain

  12. Hôpital Haut-Levèque, Pessac, France

    Carmen Botella-Garcia

  13. Hannover Medical School, Hannover, Germany

    Christian Koenecke

  14. CHU Lyon Sud, Pierre-Benite, France

    Sophie Ducastelle

  15. Hospital Universitari I politècnic La Fe, Valencia, Spain

    Jaime Sanz

  16. Antwerp University Hospital (UZA), Antwerp-Edegem, Belgium

    Wilfried Schroyens

  17. Rambam Medical Center, Haifa, Israel

    Tsila Zuckerman

  18. A.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

    Federico Monaco

  19. EBMT Data Office, Leiden, UK

    Linda Koster

  20. Leiden University Medical Center, Leiden, The Netherlands

    Liesbeth de Wreede

  21. St. James Hospital, Trinity College Dublin, Dublin, Ireland

    Patrick J. Hayden

  22. University of Heidelberg, Heidelberg, Germany

    Stefan Schönland

  23. CHU de Lille, Université de Lille, INSERM U1286, Infinite, Lille, France

    Ibrahim Yakoub-Agha

  24. Ankara University Faculty of Medicine, Ankara, Turkey

    Meral Beksac

Authors
  1. Laure Vincent
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luuk Gras
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patrice Ceballos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jürgen Finke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jakob Passweg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stéphanie Harel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Laura Rosinol
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Monique Minnema
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Raphael Teipel
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jaap van Doesum
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mathias Hänel
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Pascal Lenain
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Carmen Botella-Garcia
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Christian Koenecke
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Sophie Ducastelle
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Jaime Sanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Wilfried Schroyens
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Tsila Zuckerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Federico Monaco
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Linda Koster
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Liesbeth de Wreede
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Patrick J. Hayden
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Stefan Schönland
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Ibrahim Yakoub-Agha
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Meral Beksac
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LV, SS, and MB designed the paper. LV, PC, JF, JP, SH, LR, MM, RT, JA van D, MH, PL, EF, CK, SD, JS, WS, TZ, and FM contributed to patient recruitment. All co-authors performed research. LG performed the statistical analysis. LV, LG, SS, MBL de W, PH, and IY-A wrote the paper. All authors approved the paper. LK did the data management.

Corresponding author

Correspondence to Laure Vincent.

Ethics declarations

Competing interests

Laure Vincent: consultancy: Janssen Cilag. Monique Minemma: consultancy: Alnylam, Janssen Cilag and Gilead, speakers Bureau: BMS and hospitality from Celgene. Raphael Teipel: honoraria: Janssen. Mathias Hanel: consultancy/advisory boards: Celgene, Amgen, Novartis, Takeda, GSK, honoraria: Celgene, Novartis, Takeda. Tsila Zuckerman: advisory board or speaker’s bureau: AbbVie, Orgenesis Inc, BioSight Ltd, Cellect Biotechnology, Janssen, Novartis and Gilead Sciences. Stefan Schönland: honoraria: Janssen Cilag, Prothena, Takeda, Pfizer, research funding: Janssen Cilag, Sanofi, Prothena. Ibrahim Yakoub-Agha: honoraria: Celgene/BMS, Kite/Gilead, Janssen Cilag and Novartis. Meral Beksac: advisory board and speakers bureau: Amgen, Celgene, Janssen, Sanofi, Takeda, Oncopeptides. The remaining authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vincent, L., Gras, L., Ceballos, P. et al. Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT. Bone Marrow Transplant 57, 499–501 (2022). https://doi.org/10.1038/s41409-021-01560-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-021-01560-y

This article is cited by

Search

Advanced search

Quick links